These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 14593960)

  • 41. [Incidence of hyperoxaluria in idiopathic calcium nephrolithiasis].
    Jaeger P; Portmann L; Bugnon JM; Jacquet AF; Burckhardt P
    Schweiz Med Wochenschr; 1982 Dec; 112(49):1795-8. PubMed ID: 7178877
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Changes in urinary composition of calcium oxalate stone formers.
    Rahman B; Rahman MA
    Biomed Pharmacother; 1986; 40(3):108-10. PubMed ID: 3742009
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Counteraction of oxalate induced nitrosative stress by supplementation of l-arginine, a potent antilithic agent.
    Pragasam V; Kalaiselvi P; Sumitra K; Srinivasan S; Varalakshmi P
    Clin Chim Acta; 2005 Apr; 354(1-2):159-66. PubMed ID: 15748613
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The characteristics of the stone and urine composition in Chinese stone formers: primary report of a single-center results.
    Wu W; Yang D; Tiselius HG; Ou L; Liang Y; Zhu H; Li S; Zeng G
    Urology; 2014 Apr; 83(4):732-7. PubMed ID: 24485999
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Hyperoxaluria and renal calculi].
    Buño Soto A; Torres Jiménez R; García Puig J; Mateos Antón F
    Arch Esp Urol; 1996 Sep; 49(7):707-26. PubMed ID: 9020008
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Urolithiasis in pediatrics: analysis of 34 patients].
    Wagner U; Balzar E; Ponhold W; Khoss A; Latal D; Zwiauer K
    Z Urol Nephrol; 1987 Sep; 80(9):505-11. PubMed ID: 3687252
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effect of verapamil on urinary stone-forming risk factors.
    Sarica K; Erturhan S; Altay B
    Urol Res; 2007 Feb; 35(1):23-7. PubMed ID: 17165082
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Direct correlation between hyperoxaluria/oxalate stone disease and the absence of the gastrointestinal tract-dwelling bacterium Oxalobacter formigenes: possible prevention by gut recolonization or enzyme replacement therapy.
    Sidhu H; Schmidt ME; Cornelius JG; Thamilselvan S; Khan SR; Hesse A; Peck AB
    J Am Soc Nephrol; 1999 Nov; 10 Suppl 14():S334-40. PubMed ID: 10541258
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Intestinal Oxalobacter formigenes colonization in calcium oxalate stone formers and its relation to urinary oxalate.
    Troxel SA; Sidhu H; Kaul P; Low RK
    J Endourol; 2003 Apr; 17(3):173-6. PubMed ID: 12803990
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Combined administration of calcium and citrate reduces urinary oxalate excretion].
    Ito H
    Hinyokika Kiyo; 1991 Oct; 37(10):1107-10. PubMed ID: 1755399
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Oral calcium supplement decreases urinary oxalate excretion in patients with enteric hyperoxaluria.
    Takei K; Ito H; Masai M; Kotake T
    Urol Int; 1998; 61(3):192-5. PubMed ID: 9933846
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The etiology of urolithiasis in Udaipur (western part of India).
    Pendse AK; Singh PP
    Urol Res; 1986; 14(2):59-62. PubMed ID: 3727215
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Calcium oxalate stones and hyperoxaluria. What is certain? What is new?].
    Straub M; Hautmann RE; Hesse A; Rinnab L
    Urologe A; 2005 Nov; 44(11):1315-23. PubMed ID: 16235094
    [TBL] [Abstract][Full Text] [Related]  

  • 54. ALLN-177, oral enzyme therapy for hyperoxaluria.
    Lingeman JE; Pareek G; Easter L; Pease R; Grujic D; Brettman L; Langman CB
    Int Urol Nephrol; 2019 Apr; 51(4):601-608. PubMed ID: 30783888
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Oxalobacter formigenes: Opening the door to probiotic therapy for the treatment of hyperoxaluria.
    Jairath A; Parekh N; Otano N; Mishra S; Ganpule A; Sabnis R; Desai M
    Scand J Urol; 2015; 49(4):334-7. PubMed ID: 25645091
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Oxalate stone prophylaxis by alkalinizing therapy (author's transl)].
    Butz M
    Urologe A; 1982 May; 21(3):142-6. PubMed ID: 7048691
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The efficacy of dietary intervention on urinary risk factors for stone formation in recurrent calcium oxalate stone patients.
    Siener R; Schade N; Nicolay C; von Unruh GE; Hesse A
    J Urol; 2005 May; 173(5):1601-5. PubMed ID: 15821507
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Evaluation of the effect of triterpenes on urinary risk factors of stone formation in pyridoxine deficient hyperoxaluric rats.
    Vidya L; Lenin M; Varalakshmi P
    Phytother Res; 2002 Sep; 16(6):514-8. PubMed ID: 12237806
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparative study of the effects of pyruvate and CG-120 in preventing experimental oxalate urolithiasis in rats.
    Ogawa Y; Yamaguchi K; Tanaka T; Morozumi M
    Hinyokika Kiyo; 1986 Sep; 32(9):1341-7. PubMed ID: 3812152
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Metabolic evaluation of children with urolithiasis.
    Gouru VR; Pogula VR; Vaddi SP; Manne V; Byram R; Kadiyala LS
    Urol Ann; 2018; 10(1):94-99. PubMed ID: 29416283
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.